Business Description
Shukra Pharmaceuticals Ltd
ISIN : INE551C01028
Compare
Compare
Traded in other countries / regions
524632.India IPO Date
2000-12-26Description
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments; pharmaceutical and Laboratory. Its product portfolio includes antibiotics, antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, anti-emetic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.07 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 63.27 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.09 | |||||
| Beneish M-Score | 0.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 181.2 | |||||
| 3-Year EBITDA Growth Rate | 166.8 | |||||
| 3-Year FCF Growth Rate | -44.5 | |||||
| 3-Year Book Growth Rate | 46.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 96.22 | |||||
| 9-Day RSI | 90.79 | |||||
| 14-Day RSI | 84.34 | |||||
| 6-1 Month Momentum % | 233.39 | |||||
| 12-1 Month Momentum % | 160.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.11 | |||||
| Quick Ratio | 2.09 | |||||
| Cash Ratio | 0.38 | |||||
| Days Inventory | 9.28 | |||||
| Days Sales Outstanding | 68.08 | |||||
| Days Payable | 71.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.12 | |||||
| Dividend Payout Ratio | 0.02 | |||||
| Forward Dividend Yield % | 0.12 | |||||
| 5-Year Yield-on-Cost % | 0.12 | |||||
| 3-Year Average Share Buyback Ratio | 19.6 | |||||
| Shareholder Yield % | -0.12 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 25.05 | |||||
| Operating Margin % | 15.08 | |||||
| Net Margin % | 16.85 | |||||
| FCF Margin % | -1.2 | |||||
| ROE % | 64.46 | |||||
| ROA % | 30.75 | |||||
| ROIC % | 42.01 | |||||
| ROC (Joel Greenblatt) % | 71.21 | |||||
| ROCE % | 54.82 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.57 | |||||
| PE Ratio without NRI | 21.37 | |||||
| Shiller PE Ratio | 114.17 | |||||
| Price-to-Owner-Earnings | 64.01 | |||||
| PEG Ratio | 0.27 | |||||
| PS Ratio | 2.05 | |||||
| PB Ratio | 10.63 | |||||
| Price-to-Tangible-Book | 10.63 | |||||
| Price-to-Operating-Cash-Flow | 22.73 | |||||
| EV-to-EBIT | 24.47 | |||||
| EV-to-EBITDA | 22.09 | |||||
| EV-to-Revenue | 4.2 | |||||
| EV-to-FCF | -349.72 | |||||
| Price-to-Median-PS-Value | 1.66 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.87 | |||||
| Earnings Yield (Greenblatt) % | 4.09 | |||||
| FCF Yield % | -0.28 | |||||
| Forward Rate of Return (Yacktman) % | 20.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shukra Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,099.348 | ||
| EPS (TTM) (₹) | 5.209 | ||
| Beta | 0.17 | ||
| Volatility % | 124.84 | ||
| 14-Day RSI | 84.34 | ||
| 14-Day ATR (₹) | 2.008015 | ||
| 20-Day SMA (₹) | 91.700375 | ||
| 12-1 Month Momentum % | 160.66 | ||
| 52-Week Range (₹) | 20.425 - 107.16 | ||
| Shares Outstanding (Mil) | 43.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shukra Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shukra Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shukra Pharmaceuticals Ltd Frequently Asked Questions
What is Shukra Pharmaceuticals Ltd(BOM:524632)'s stock price today?
The current price of BOM:524632 is ₹107.16. The 52 week high of BOM:524632 is ₹107.16 and 52 week low is ₹20.43.
When is next earnings date of Shukra Pharmaceuticals Ltd(BOM:524632)?
The next earnings date of Shukra Pharmaceuticals Ltd(BOM:524632) is .
Does Shukra Pharmaceuticals Ltd(BOM:524632) pay dividends? If so, how much?
The Dividend Yield %  of Shukra Pharmaceuticals Ltd(BOM:524632) is 0.12% (As of Today), Highest Dividend Payout Ratio of Shukra Pharmaceuticals Ltd(BOM:524632) was 2.17. The lowest was 0. And the median was 0.16. The  Forward Dividend Yield % of Shukra Pharmaceuticals Ltd(BOM:524632) is 0.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers